Hoth Therapeutics (NASDAQ:HOTH), a US-based clinical-stage biopharmaceutical company focused on developing innovative therapies for underserved medical needs, announced on Friday an expansion of its intellectual property portfolio with the filing of two provisional patent applications in the United States, establishing a new oncology-focused dermatology platform targeting treatment-induced skin toxicity from modern cancer therapies.

The first provisional patent application covers the topical treatment of radiation-induced skin toxicity in oncology patients, while the second addresses dermatologic toxicities associated with emerging targeted cancer therapies, including second and third menin inhibitors.

Together, these dual filings secure priority intellectual property rights around the use of HT-001 to treat dermatologic toxicities across multiple oncology treatment modalities, including radiation therapy and next-generation targeted agents.

Hoth is seeking to protect the use of HT-001, a receptor antagonist with a well-established pharmacologic profile, to target neurogenic and inflammatory pathways implicated in therapy-induced skin injury. The company believes this approach may represent a novel and potentially first-in-class strategy within the rapidly expanding oncology supportive-care and oncodermatology markets.